Ocular inflammation therapeutic - Tibet Rhodiola PharmaceuticalAlternative Names: Recombinant human interleukin-1 receptor antagonist protein - Tibet Rhodiola Pharmaceutical
Latest Information Update: 27 Nov 2015
At a glance
- Originator Tibet Rhodiola Pharmaceutical Holding Co Ltd
- Mechanism of Action Interleukin 1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Ocular inflammation
Most Recent Events
- 27 Nov 2015 Clinical trials in Ocular inflammation in China (Ophthalmic)